Drug intelligence / Profile preview

NuroPro

Development stage: Preclinical
Lead developer: Power3 Medical Products
Modality: Recombinant Proteins and Enzymes
Administration: Transdermal

Overview

NuroPro is a program or product line developed by Amarantus BioSciences and Rainbow BioSciences Corporation for Parkinson's disease. It is linked to the Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) therapeutic, a protein that protects neurons from endoplasmic reticulum (ER) stress-associated complications by restoring ER homeostasis and regulating the unfolded protein response (UPR). MANF also exhibits neuroprotective, neurorestorative, anti-inflammatory, and anti-apoptotic effects, particularly beneficial for dopaminergic neurons. Additionally, NuroPro encompasses a diagnostic blood test for Parkinson's disease.

Brand names: NuroPro

Beyond the preview

Go deeper on NuroPro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuroPro.

Explore the full profile